Kevin Church - 19 Jan 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Executive VP, Research
Signature: /s/ Glenna Mileson, Attorney-in-Fact for Kevin Church
Issuer symbol: ATHA
Transactions as of: 19 Jan 2023
Net transactions value: +$1,800
Form type: 4
Filing time: 23 Jan 2023, 16:26:34 UTC
Previous filing: 31 Oct 2022
Next filing: 27 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$1,800	+657	+1.1%	$2.74	62,052	18 Nov 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Award	$0	+150,000		$0.000000	150,000	19 Jan 2023	Common Stock	150,000	$3.37	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).
F2	The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.
F4	One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.